Screener
Mineralys Therapeutics, Inc. MLYS Net Income
Net Income at other companies
Other financials
Where this comes from
Reported directly by Mineralys Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Mineralys Therapeutics, Inc.’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 5:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001933414-26-000084
| Line item | Three Months Ended / March 31, 2026 | 2025 |
|---|---|---|
| Total operating expenses | 45,340 | 44,447 |
| Loss from operations | (45,340) | (44,447) |
| Interest income, net | 5,996 | 2,239 |
| Other income (expense) | 5 | (3) |
| Total other income, net | 6,001 | 2,236 |
| Net loss | $(39,339) | $(42,211) |
| Net loss per share attributable to common stockholders, basic and diluted | $(0.47) | $(0.79) |
| Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted | 82,834,752 | 53,163,551 |
Item 1. Financial Statements
FAQ
- What is Mineralys Therapeutics, Inc.'s net income?
- Mineralys Therapeutics, Inc. (MLYS) reported net income of -$39.34M in Q1 2026.
- How has Mineralys Therapeutics, Inc.'s net income changed year-over-year?
- Mineralys Therapeutics, Inc.'s net income increased by 6.8% year-over-year, from -$42.21M to -$39.34M.
- What is the long-term trend for Mineralys Therapeutics, Inc.'s net income?
- Over 3 years (2022 to 2025), Mineralys Therapeutics, Inc.'s net income has grown at a 73.1% compound annual growth rate (CAGR), from -$29.8M to -$154.65M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about Mineralys Therapeutics, Inc.'s net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude